(Total Views: 427)
Posted On: 10/13/2024 8:41:21 AM
Post# of 154656
Viking competition for Madrigal on our MASH rights?
" without worsening of liver scarring, or fibrosis, after 52 weeks in data reported back in February."
"But VK2809 could also have some benefit to a buyer, because the drug demonstrated fibrosis improvement in the midstage trial where Madrigal’s Rezdiffra did not.
https://www.fiercebiotech.com/biotech/vikings...-direction
____
We know "without worsening", is nowhere near the same as what our MASH reported: "significantly reversed".
Viking + a partner ÷ our MASH ?
The reason their CEO was being careful with words in this interview ?
" without worsening of liver scarring, or fibrosis, after 52 weeks in data reported back in February."
"But VK2809 could also have some benefit to a buyer, because the drug demonstrated fibrosis improvement in the midstage trial where Madrigal’s Rezdiffra did not.
https://www.fiercebiotech.com/biotech/vikings...-direction
____
We know "without worsening", is nowhere near the same as what our MASH reported: "significantly reversed".
Viking + a partner ÷ our MASH ?
The reason their CEO was being careful with words in this interview ?
(2)
(0)
